An integrated portable system for single chip simultaneous measurement of multiple disease associated metabolites.

Metabolites, the small molecules that underpin life, can act as indicators of the physiological state of the body when their abundance varies, offering routes to diagnosis of many diseases. The ability to assay for multiple metabolites simultaneously will underpin a new generation of precision diagnostic tools. Here, we report the development of a handheld device based on complementary metal oxide semiconductor (CMOS) technology with multiple isolated micro-well reaction zones and integrated optical sensing allowing simultaneous enzyme-based assays of multiple metabolites (choline, xanthine, sarcosine and cholesterol) associated with multiple diseases. These metabolites were measured in clinically relevant concentration range with minimum concentrations measured: 25 μM for choline, 100 μM for xanthine, 1.25 μM for sarcosine and 50 μM for cholesterol. Linking the device to an Android-based user interface allows for quantification of metabolites in serum and urine within 2 min of applying samples to the device. The quantitative performance of the device was validated by comparison to accredited tests for cholesterol and glucose.

[1]  Ara W. Darzi,et al.  Metabolic phenotyping in clinical and surgical environments , 2012, Nature.

[2]  M. Möckel,et al.  Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability , 2010, Expert review of molecular diagnostics.

[3]  Yi Shi,et al.  A nanostructured conductive hydrogels-based biosensor platform for human metabolite detection. , 2015, Nano letters.

[4]  Vahid Sandoghdar,et al.  Direct optical sensing of single unlabelled proteins and super-resolution imaging of their binding sites. , 2014, Nature communications.

[5]  Noma Akio,et al.  New enzymatic assay of cholinesterase activity. , 1977 .

[6]  Boon Chong Cheah,et al.  Immunoassay Multiplexing on a Complementary Metal Oxide Semiconductor Photodiode Array , 2018, ACS sensors.

[7]  Lei Xi,et al.  Inosine and hypoxanthine as novel biomarkers for cardiac ischemia: From bench to point-of-care , 2015, Experimental biology and medicine.

[8]  M. Suzuki Purification and some properties of sarcosine oxidase from Corynebacterium sp. U-96. , 1981, Journal of biochemistry.

[9]  Matthew G. Vander Heiden,et al.  Altered metabolite levels in cancer: implications for tumour biology and cancer therapy , 2016, Nature Reviews Cancer.

[10]  Kenneth L. Shepard,et al.  Electrochemical camera chip for simultaneous imaging of multiple metabolites in biofilms , 2016, Nature Communications.

[11]  V. Adam,et al.  Sarcosine as a Potential Prostate Cancer Biomarker—A Review , 2013, International journal of molecular sciences.

[12]  David R. S. Cumming,et al.  Hybrid Dual Mode Sensor for Simultaneous Detection of Two Serum Metabolites , 2018, IEEE Sensors Journal.

[13]  O. Ali,et al.  Ischemic heart diseases in Egypt: role of xanthine oxidase system and ischemia-modified albumin , 2014, Heart and Vessels.

[14]  G. Roussos [1] Xanthine oxidase from bovine small intestine , 1967 .

[15]  H. Simmonds,et al.  Acute renal failure due to xanthine stones , 1995, Pediatric Nephrology.

[16]  P. Serruys,et al.  Hypoxanthine production by ischemic heart demonstrated by high pressure liquid chromatography of blood purine nucleosides and oxypurines. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[17]  Roberto A Chica,et al.  Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. , 2005, Current opinion in biotechnology.

[18]  S. Gutnikov,et al.  Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison , 2007, The Lancet.

[19]  A. Pineda-Lucena,et al.  Metabolomics Applications in Precision Medicine: An Oncological Perspective , 2017, Current topics in medicinal chemistry.

[20]  M. Adamczyk,et al.  Choline concentration in normal blood donor and cardiac troponin-positive plasma samples. , 2006, Clinical chemistry.

[21]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[22]  Toshifumi Takeuchi,et al.  Molecularly imprinted protein recognition cavities bearing exchangeable binding sites for postimprinting site-directed introduction of reporter molecules for readout of binding events. , 2014, ACS applied materials & interfaces.

[23]  G. Smith,et al.  Mendelian randomization in cardiometabolic disease: challenges in evaluating causality , 2017, Nature Reviews Cardiology.

[24]  E. Rice,et al.  Determination of glucose by an improved enzymatic procedure. , 1961, Clinical chemistry.

[25]  M. Möckel,et al.  Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. , 2003, The American journal of cardiology.

[26]  J. Greenslade,et al.  Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. , 2016, JAMA cardiology.

[27]  David R. S. Cumming,et al.  A Colorimetric CMOS-Based Platform for Rapid Total Serum Cholesterol Quantification , 2017, IEEE Sensors Journal.

[28]  A. Fernie,et al.  Metabolite profiling: from diagnostics to systems biology , 2004, Nature Reviews Molecular Cell Biology.

[29]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[30]  D. M. Amundson,et al.  Fluorometric method for the enzymatic determination of cholesterol. , 1999, Journal of biochemical and biophysical methods.

[31]  G S Rautela,et al.  Automated enzymic measurement of total cholesterol in serum. , 1978, Clinical chemistry.

[32]  R. Martino,et al.  Uses and Limitations of Nuclear Magnetic Resonance (NMR) Spectroscopy in Clinical Pharmacokinetics , 1991, Clinical pharmacokinetics.

[33]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[34]  Luigi Atzori,et al.  Metabolomics as a tool for cardiac research , 2011, Nature Reviews Cardiology.

[35]  D. Mendrick,et al.  Genomic and metabolomic advances in the identification of disease and adverse event biomarkers. , 2009, Biomarkers in medicine.

[36]  Edward T Chouchani,et al.  Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS , 2014, Nature.

[37]  M. Walters,et al.  Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? , 2006, British journal of clinical pharmacology.

[38]  Daniel Raftery,et al.  Early detection of recurrent breast cancer using metabolite profiling. , 2010, Cancer research.

[39]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[40]  Lan Huang,et al.  Three plasma metabolite signatures for diagnosing high altitude pulmonary edema , 2015, Scientific Reports.

[41]  Michael P. Barrett,et al.  An Integrated Circuit for Chip-Based Analysis of Enzyme Kinetics and Metabolite Quantification , 2016, IEEE Transactions on Biomedical Circuits and Systems.

[42]  Rona S. Gertner,et al.  CMOS nanoelectrode array for all-electrical intracellular electrophysiological imaging. , 2017, Nature nanotechnology.

[43]  E. Carrilho,et al.  Towards low-cost bioanalytical tools for sarcosine assays for cancer diagnostics , 2016 .